FDA 483 - Neos Therapeutics, LP - August 25, 2023
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Neos Therapeutics, LP, a drug manufacturer in Grand Prairie, TX, was cited for two significant observations during an FDA inspection. The firm failed to appropriately validate component supplier test results and update product specifications according to a new USP monograph for Polyethylene Glycol. Additionally, the company did not follow established laboratory control mechanisms, specifically regarding the accountability of raw laboratory data sheets used for dissolution testing.
ID · 1034721b-9c51-4024-b271-5cf9eb7e7700